Luminal A | Luminal B | Triple negative | HER2/Neu | |
---|---|---|---|---|
Number of the patients | 11 (44%) | 5 (20%) | 3 (12%) | 6 (24%) |
Age | 52.09 ± 14.88 | 51.60 ± 13.54 | 53.33 ± 6.66 | 57.17 ± 10.80 |
Range: 29–79 | Range: 29–63 | Range: 46–59 | Range: 43–75 | |
Histological type of the carcinoma | Invasive ductal: 8 (72.7%) | Invasive ductal: 4 (80%) | Invasive ductal: 3 (100%) | Invasive ductal: 6 (100%) |
Invasive lobular: 3 (27.3%) | Invasive lobular: 1 (20%) | Invasive lobular: 0 (0%) | Invasive lobular: 0 (0%) | |
Grade | I: 0 (0%) | I: 1 (20%) | I: 0 (0%) | I: 0 (0%) |
II: 8 (72.7%) | II: 2 (40%) | II: 2 (66.7%) | II: 3 (50%) | |
III: 3 (27.3%) | III: 2 (40%) | III: 1 (33.3%) | III: 3 (50%) | |
LN | Positive: 9 (81.8%) | Positive: 3 (60%) | Positive: 2 (66.7%) | Positive: 6 (100%) |
Negative: 2 (18.2%) | Negative: 2 (40%) | Negative: 1 (33.3%) | Negative: 0 (0%) | |
Metastasis | Positive: 5 (45.5%) | Positive: 0 (0%) | Positive: 2 (66.7%) | Positive: 2 (33.3%) |
Negative: 6 (54.5%) | Negative: 5 (100%) | Negative: 1 (33.3%) | Negative: 4 (66.7%) | |
Ki67 | 33.27 ± 18.14 | 27.4 ± 8.88 | 30 ± 7 | 34.17 ± 9.33 |
Range: 20–85 | Range: 12–35 | Range: 25–38 | Range: 25–50 | |
Liver SUVmax | 2.08 ± 0.73 | 2.06 ± 0.40 | 1.67 ± 0.15 | 2.27 ± 0.70 |
Range: 1.2–3.8 | Range: 1.5–2.5 | Range: 1.5–1.8 | Range: 1.3–2.9 | |
Spleen SUVmax | 1.78 ± 0.54 | 1.92 ± 0.66 | 1.47 ± 0.15 | 2.27 ± 0.82 |
Range: 1–1.3 | Range: 1.1–2.9 | Range: 1.3–1.6 | Range: 1.2–3.1 |